ArticleFrontiers in oncology2025
Predicting IDH and 1p/19q molecular status of gliomas with multi-b values DWI.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.Neuro-oncology · 2026Review
- ASL perfusion radiomic heterogeneity is associated with early mortality in IDH-wildtype glioblastoma, beyond tumor volume: a time-varying effect with tumor-aware DTI-ALPS.Frontiers in oncology · 2026Article
- Multimodal artificial intelligence in glioma management: integrating neuroimaging and hematologic biomarkers for precision oncology.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: In the 2021 WHO Classification, the importance of molecular pathology in glioma diagnosis has been emphasized, particularly the status of isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion. Advanced magnetic resonance diffusion-weighted imaging (DWI) including mono-exponential (Mono), intravoxel incoherent motion (IVIM), stretched exponential model (SEM) techniques are beneficial for non-invasive prediction of these molecular markers. The continuous-time random walk (CTRW) model mitigates the empirical nature of the SEM and has shown promising results in grading gliomas. However, the application of CTRW model in prediction of IDH and 1p/19q molecular phenotypes in adult diffuse gliomas remains underreported. This study compares the clinical utility of mono-exponential, IVIM, SEM, and CTRW models for predicting IDH and 1p/19q molecular status in adult diffuse gliomas. Materials and methods: Data of adult diffuse glioma patients from January 2021 to August 2023 were collected. The multi-b-value DWI was acquired using a spin-echo echo-planar imaging sequence with 13 b-values (0, 10, 20, 30, 50, 70, 100, 150, 200, 400, 800, 1500, 2000 s/mm²) in 30 diffusion-encoding directions. Multi-b-value DWI images were post-processed to generate parametric maps based on the mono-exponential (Mono), the intravoxel incoherent motion (IVIM), the stretched exponential model (SEM) and the continuous-time random walk (CTRW) models. The mean parameter values of solid tumor regions were calculated. An independent sample Results: A total of 95 glioma patients were included in the study. For predicting IDH status, CTRW_α exhibited the largest effect size and best diagnostic performance with an AUC of 0.761. At a threshold of 0.855, the sensitivity was 0.651, the specificity was 0.846, and the accuracy was 0.758. In predicting 1p/19q status in IDH-mutant gliomas, CTRW_α again showed the largest effect size and the best diagnostic performance with an AUC of 0.790. At a threshold of 0.886, sensitivity was 0.750, specificity was 0.903, and accuracy was 0.860. Conclusions: The CTRW model could help predict IDH and 1p/19q status in adult diffuse gliomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.